May 9, 2017. Good afternoon. I appreciate the opportunity to address this distinguished panel and our FDA participants. I’m Jack Mitchell, director of government relations for the National Center for Health Research (NCHR). We conduct research, use research data to inform public policy, and advocate for safe and effective medical products. NCHR accepts no pharmaceutical or medical device industry money, and therefore I have no conflicts to report.
April 12, 2017. Based on its previous review, the USPSTF recommended risk assessment, genetic testing, and counseling for women with a family history of clinically important mutations in BRCA1 or BRCA2 genes.
April 19, 2017. In their previous recommendation, USPSTF found that treatment with tamoxifen or raloxifene was beneficial for a subpopulation of women at increased risk. However, these treatments only slightly reduced the occurrence of invasive breast cancer in these women and came with serious risks
These are the materials from the Senate briefing we hosted on March 4, 2016 with the Patient, Consumer, and Public Health Coalition titled “Innovation for Healthier Americans: The Impact of Proposed Health Bills on Patients & Consumers”.
By Dr. Anna Mazzucco January 8, 2015 Thank you for the opportunity to speak today at this very important meeting. My name is Dr. Anna Mazzucco, and I am speaking on behalf of the National Center for Health Research. I received my Ph.D. in cell biology from Harvard Medical School, and I conducted post-doctoral […]
December 3, 2014. Research has implicated endocrine-disrupting chemicals in cancer, infertility, and other health problems. We must be able to quickly identify such agents in order to prevent them from entering our food and environment, and from affecting our health for generations to come.